Roivant Sciences price target lowered to $15 from $16 at JPMorgan

JPMorgan lowered the firm’s price target on Roivant Sciences to $15 from $16 and keeps an Overweight rating on the shares. The analyst removed the stand-alone assumption for Telavant and reflected the anticipated capital inflow on the balance sheet. Roivant’s underlying fundamentals remain solid heading into a number of catalysts in the coming quarters and the recent weakness in shares is an attractive entry opportunity, the analyst tells investors in a research note.